Literature DB >> 23679874

Molecularly targeted therapies for nonmelanoma skin cancers.

Lucinda S Liu1, Oscar R Colegio.   

Abstract

Over the past two decades, advances in the fields of cancer genetics and molecular biology have elucidated molecular pathways that cause numerous cutaneous malignancies. This in turn has spurred the rational design of molecularly targeted therapies. In this review, we discuss the molecular pathways critical to the development of nonmelanoma skin cancers and the novel pharmacologic agents that target them. Included is a review of vismodegib for basal cell carcinoma, cetuximab for squamous cell carcinomas, imatinib for dermatofibrosarcoma protuberans, and sirolimus for Kaposi's sarcoma.
© 2013 The International Society of Dermatology.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23679874     DOI： 10.1111/ijd.12017

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN： 0011-9059            Impact factor:   2.736


  9 in total

1.  TLR4 in skin cancer: From molecular mechanisms to clinical interventions.

Authors:  Sally E Dickinson; Georg T Wondrak
Journal:  Mol Carcinog       Date:  2019-04-24       Impact factor: 4.784

2.  Polymeric Nanoparticles to Combat Squamous Cell Carcinomas in Patients with Dystrophic Epidermolysis Bullosa.

Authors:  Martin A C Manoukian; Susanne V Ott; Jayakumar Rajadas; Mohammed Inayathullah
Journal:  Recent Pat Nanomed       Date:  2014

3.  Fluorescence in situ hybridization analysis is a helpful test for the diagnosis of dermatofibrosarcoma protuberans.

Authors:  Marie Karanian; Gaëlle Pérot; Jean-Michel Coindre; Frédéric Chibon; Florence Pedeutour; Agnès Neuville
Journal:  Mod Pathol       Date:  2014-08-01       Impact factor: 7.842

4.  Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin.

Authors:  Sally E Dickinson; Jaroslav Janda; Jane Criswell; Karen Blohm-Mangone; Erik R Olson; Zhonglin Liu; Christy Barber; Emanuel F Petricoin; Valerie S Calvert; Janine Einspahr; Jesse E Dickinson; Steven P Stratton; Clara Curiel-Lewandrowski; Kathylynn Saboda; Chengcheng Hu; Ann M Bode; Zigang Dong; David S Alberts; G Timothy Bowden
Journal:  Cancer Prev Res (Phila)       Date:  2016-01-22

5.  [Genodermatoses with malignant skin tumors].

Authors:  L Hübinger; J Frank
Journal:  Hautarzt       Date:  2014-06       Impact factor: 0.751

6.  Immunohistochemical analysis of the mechanistic target of rapamycin and hypoxia signalling pathways in basal cell carcinoma and trichoepithelioma.

Authors:  Tjinta Brinkhuizen; Chantal A H Weijzen; Jonathan Eben; Monique R Thissen; Ariënne M van Marion; Björn G Lohman; Véronique J L Winnepenninckx; Patty J Nelemans; Maurice A M van Steensel
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

7.  Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype.

Authors:  Christian Koelsche; Damian Stichel; Klaus G Griewank; Daniel Schrimpf; David E Reuss; Melanie Bewerunge-Hudler; Christian Vokuhl; Winand N M Dinjens; Iver Petersen; Michel Mittelbronn; Adrian Cuevas-Bourdier; Rolf Buslei; Stefan M Pfister; Uta Flucke; Gunhild Mechtersheimer; Thomas Mentzel; Andreas von Deimling
Journal:  Clin Sarcoma Res       Date:  2019-02-14

Review 8.  Skin Carcinogenesis Studies Using Mouse Models with Altered Polyamines.

Authors:  Shannon L Nowotarski; David J Feith; Lisa M Shantz
Journal:  Cancer Growth Metastasis       Date:  2015-08-09

Review 9.  Advances in the management of cutaneous squamous cell carcinoma.

Authors:  Sonal A Parikh; Vishal A Patel; Desiree Ratner
Journal:  F1000Prime Rep       Date:  2014-08-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.